Atara Biotherapeutics (NASDAQ:ATRA) was downgraded by Citigroup from a “neutral” rating to a “sell” rating in a research report issued to clients and investors on Thursday, The Fly reports.

Several other research firms also recently weighed in on ATRA. BidaskClub upgraded Atara Biotherapeutics from a “buy” rating to a “strong-buy” rating in a research note on Tuesday. ValuEngine upgraded Atara Biotherapeutics from a “sell” rating to a “hold” rating in a research note on Friday, February 2nd. Zacks Investment Research downgraded Atara Biotherapeutics from a “hold” rating to a “sell” rating in a research note on Tuesday, February 6th. Cowen assumed coverage on Atara Biotherapeutics in a research note on Friday, January 26th. They set an “outperform” rating on the stock. Finally, Canaccord Genuity reiterated a “positive” rating and set a $70.00 price target (up previously from $47.00) on shares of Atara Biotherapeutics in a research note on Friday, January 19th. Two research analysts have rated the stock with a sell rating, two have issued a hold rating, four have assigned a buy rating and one has given a strong buy rating to the company’s stock. The company has a consensus rating of “Hold” and an average target price of $30.60.

Shares of Atara Biotherapeutics (NASDAQ:ATRA) opened at $48.35 on Thursday. The firm has a market capitalization of $1,693.69, a PE ratio of -13.93 and a beta of 2.71. Atara Biotherapeutics has a one year low of $11.80 and a one year high of $49.90.

In other news, EVP Gad Soffer sold 7,000 shares of the business’s stock in a transaction dated Friday, November 17th. The stock was sold at an average price of $15.00, for a total value of $105,000.00. Following the completion of the transaction, the executive vice president now owns 166,342 shares of the company’s stock, valued at approximately $2,495,130. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, CEO Isaac E. Ciechanover sold 4,400 shares of the business’s stock in a transaction dated Thursday, November 30th. The shares were sold at an average price of $14.25, for a total value of $62,700.00. The disclosure for this sale can be found here. In the last three months, insiders sold 297,914 shares of company stock valued at $8,074,587. Insiders own 16.20% of the company’s stock.

Several hedge funds have recently modified their holdings of the company. Nexthera Capital LP acquired a new position in shares of Atara Biotherapeutics in the 4th quarter valued at about $5,188,000. Raymond James & Associates lifted its holdings in shares of Atara Biotherapeutics by 7.3% in the 4th quarter. Raymond James & Associates now owns 25,325 shares of the biotechnology company’s stock valued at $458,000 after buying an additional 1,719 shares during the period. Bridger Management LLC lifted its holdings in shares of Atara Biotherapeutics by 57.3% in the 4th quarter. Bridger Management LLC now owns 2,598,599 shares of the biotechnology company’s stock valued at $47,035,000 after buying an additional 946,086 shares during the period. California State Teachers Retirement System lifted its holdings in shares of Atara Biotherapeutics by 4.6% in the 4th quarter. California State Teachers Retirement System now owns 42,159 shares of the biotechnology company’s stock valued at $763,000 after buying an additional 1,836 shares during the period. Finally, Deutsche Bank AG lifted its holdings in shares of Atara Biotherapeutics by 178.5% in the 4th quarter. Deutsche Bank AG now owns 71,085 shares of the biotechnology company’s stock valued at $1,285,000 after buying an additional 45,565 shares during the period. 69.58% of the stock is owned by institutional investors and hedge funds.

COPYRIGHT VIOLATION NOTICE: “Atara Biotherapeutics (ATRA) Downgraded by Citigroup” was originally published by The Cerbat Gem and is owned by of The Cerbat Gem. If you are accessing this report on another publication, it was illegally stolen and republished in violation of United States and international trademark and copyright legislation. The correct version of this report can be viewed at https://www.thecerbatgem.com/2018/02/15/atara-biotherapeutics-atra-downgraded-by-citigroup.html.

Atara Biotherapeutics Company Profile

Atara Biotherapeutics, Inc is a clinical-stage biopharmaceutical company. The Company is focused on developing therapies for patients with severe and life-threatening diseases. The Company operates through the business of developing and commercializing therapeutics segment. The Company is focused on developing allogeneic or third-party derived antigen-specific T-cells.

The Fly

Analyst Recommendations for Atara Biotherapeutics (NASDAQ:ATRA)

Receive News & Ratings for Atara Biotherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Atara Biotherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.